A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia

Journal of Molecular Diagnostics

Volumn 11, Issue 4, 2009, Pages 319-323

  Ahn, Jeung Yeal ^a,b   Seo, Katie ^a   Weinberg, Olga ^a   Boyd, Scott D ^a   Arber, Daniel A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CEBPA GENE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; VALIDITY;

ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 69249158766     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080121     Document Type: Article

References (20)

1. Tenen DG, Hromas R, Licht JD, Zhang DE: Transcription factors, normal myeloid development and leukemia. Blood 1997, 90:489-519
2. van Waalwijk van Doorn-Khosravani SB, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WLJ, Valk PJM, Beverloo HB, Tenen DG, Löwenberg B, Delwel R: Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediaterisk AML. Hematol J 2003, 4:31-40
3. Schwieger M, Löhler J, Fischer M, Herwig U, Tenen DG, Stocking C: A dominant-negative mutant of C/EBPα, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood 2004, 103:2744-2752
4. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α(C/EBPα), in acute myeloid leukemia. Nat Genet 2001, 27:263-270
5. Snaddon AJ, Smith ML, Neat M, Cambal-Parrales M, Dixon-Mclver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J: Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003, 37:72-78
6. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2003, 100:2717-2723
7. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 15:1-10
8. Bienz M, Ludwig M, Mueller BU, Leibundgut EO, Ratschiller D, Solenthaler M, Fey MF, Pabst T: Risk assessment inpatients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005, 15:1416-1424
9. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF: Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11:1372-1379
10. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008
11. Lin LI, Lin TC, Chou WC, Tang JL, Lin DT, Tien HF: A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia 2006, 20:1899-1903
12. Wouters BJ, Louwers I, Valk PJM, Löwenberg B, Delwel R: A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering in AML. Blood 2007, 109:389-390
13. Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, Kobylka P, Cermak J, Brezinova J, Schwarz J, Markova J, Salaj P, Klamova H, Maaloufova J, Lemez P, Novakova L, Benesova K: CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008, 40:401-405
14. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG: CCAAT/enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998, 18:4301-4314
15. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α deficient mice. Proc Natl Acad Sci 1997, 94:569-574
16. Antonson P, Xanthopoulos KG: Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha(C/BEP alpha). Biochem Biophys Res Commun 1995, 215:106-113
17. Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M, DiPersio JF, Link DC, Tomasson MH, Graubert TA, McLeod H, Khoury H, Watson M, Shannon W, Trinkaus K, Heath S, Vardiman JW, Caligiuri MA, Bloomfield CD, Milbrandt JD, Mardis ER, Wilson RK: A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci 2003, 100:14275-14280
18. Strausberg RL, Simpson AJG, Wooster R: Sequence-based cancer genomics: progress, lessons and opportunities. Nat Rev Genet 2003, 4:409-418
19. Weber BL: Cancer genomics. Cancer Cell 2002, 1:37-47
20. Smith TA, Whelan J, Parry PJ: Detection of single-base mutations in a mixed population of cells. Genet Anal Tech Appl 1992, 9:143-145